In this report, we describe our experience with highdose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) in 15 children with relapsed osteosarcoma who were treated by members of the Cooperative Osteosarcoma Study Group. Eight patients received HDC after the first relapse, six patients after the second relapse and one after the sixth relapse. Thirteen patients underwent HDC and ASCT in complete remission and two patients had macroscopic tumor residues. Seven patients received HDC based on melphalan and etoposide. Four of these patients were treated with additional carboplatinum. Two patients received carboplatinum, etoposide, and thiotepa or cyclophosphamide. In six patients double HDC was performed. In all six of these, the first HDC consisted of thiotepa/ cyclophosphamide. The second regimens included melphalan/etposide (two patients), melphalan/etposide/ carboplatinum (one patient), and melphalan/busulfan (one patient). Three of the 15 patients died of toxic complications. Eight patients developed further relapses, two patients showed persistent disease, and two patients are presently in continuous complete remission. The probability of relapse-free survival was 0.20 ؎ 0.12 within a median follow-up (MFU) of 8 months and the probability of overall survival was 0.29 ؎ 0.12 after a MFU of 16 months. In conclusion, utilization of HDC and ASCT in this patient group did not significantly improve the treatment outcome compared to conventional relapse therapy. Bone Marrow Transplantation (2001) 27, 933-937.
therapy protocols based on high-dose methotrexate, ifosfamide, cisplatin, and doxorubicin, approximately 70% of patients with localized osteosarcoma achieve long-term remission. 1, 2 In spite of these excellent results, patients with metastatic disease or local regional relapses still have a poor prognosis. The search for useful therapeutic strategies for these patients is therefore an important point of clinical investigation. High-dose chemotherapy with autologous stem cell rescue was recently introduced for the treatment of various malignant solid tumors in children, 3, 4 but only a few studies have focused on osteosarcoma. 5 In published reports on HDC in this disease, several conditioning regimens have been used, including high-dose thiotepa, melphalan, cyclophosphamide, busulfan, and VP-16. 6 The combination of high-dose melphalan and high-dose VP-16 may represent a useful option for several refractory solid tumors in adults as well as in pediatric soft tissue sarcomas. 7, 8 In other studies describing treatment of refractory malignancies, combinations of high-dose alkylating agents were reported as being effective. 9, 10 Until now, however, there has been no established protocol for high-dose chemotherapy in osteosarcoma. All published studies have included only small patient numbers and heterogeneous treatment regimens. In this report, we present the experience obtained by members of the Cooperative GermanAustrian-Swiss Osteosarcoma Study Group (COSS) with high-dose chemotherapy in 15 children and young adults with relapsed osteosarcoma.
Patients and methods
The COSS database was searched for all patients who had received HDC and ASCT at any time during treatment for osteosarcoma. Fifteen patients were identified and all were included in this retrospective analysis. Patient characteristics are given in Table 1 . The median age at the time of the primary diagnosis was 15 years (range 6-21) and was 17 years (range 7-26) at the time when HD chemotherapy was performed. Six patients were female and nine were male. The primary tumor sites were femur (nine patients), tibia (three patients), and humerus (three patients). Twelve patients had localized disease and three patients showed 11 The histopathological evaluation of the tumor specimens after preoperative chemotherapy showed a good response in seven (Ͻ10% viable tumor) and a poor response in eight tumors. All patients achieved a first complete remission.
Relapses leading to high-dose chemotherapy involved the lung as the only site in nine patients. Two patients had combined pulmonary and local relapses, two patients had mediastinal involvement and two patients had isolated local recurrences.
Before high-dose chemotherapy was performed, all patients were treated with surgery after adjuvant conventional chemotherapy in order to achieve a further complete remission. In 13 patients, a macroscopically complete resection of all known tumor manifestations could be achieved, whereas two were left with macroscopic tumor residue following surgery. Table 2 summarizes the conventional chemotherapy given prior to HDC. Ten patients received carboplatinum/etoposide (two to four cycles) either alone or in combination with high-dose ifosfamide or cyclophosphamide. Two patients were treated with cyclophosphamide/etoposide, one with ifosfamide as a single agent, and two patients received ifosfamide and etoposide. Sufficient stem cell mobilization was achieved in all but two after conventional chemotherapy and filgrastim treatment. For two patients autologous bone marrow was harvested.
According to the disease status, high-dose chemotherapy was administered during second remission in eight patients, in third remission in five patients and in second relapse in two patients. The preparation regimens for high-dose chemotherapy were heterogeneous (Table 3) . The majority of patients were treated using conditioning protocols based on melphalan and etoposide. Out of these seven patients, four were treated with additional carboplatinum. Two patients received carboplatinum, etoposide, plus either thiotepa or cyclophosphamide. In the six remaining patients, double high-dose chemotherapy was performed. The first cycle of conditioning chemotherapy consisted of thiotepa/ cyclophosphamide in all six patients. Drugs used for the second course included melphalan/etoposide (two patients), melphalan/etoposide/carboplatinum (one patient), and melphalan/busulfan (three patients).
Results
Outcomes following treatment are summarized in Table 2 . After a median follow-up of 16 months for all patients and 9 months for survivors, 10 patients had died and five were still alive, two of them relapse-free, for a probability of overall and relapse-free survival of 29 Ϯ 0.12 and 0.20 Ϯ 0.12, respectively (Figures 1 and 2 ).
Three out of 15 patients treated with high-dose chemotherapy as salvage treatment for osteosarcoma relapses died of complications. The preparation regimens for patients who experienced toxic deaths were double conditioning with thiotepa/cyclophosphamide and melphalan/busulfan in two patients and a single course of melphalan/ etoposide/carboplatinum in one. In all of these three patients, high-dose chemotherapy had been performed in second remission. Both patients received conventional chemotherapy with carboplatinum/etoposide and the third patient received two cycles of high-dose ifosfamide in combination with etoposide. After HDC, all three patients developed symptoms compatible with septic shock, followed by capillary leakage and multiorgan failure.
Of the 12 patients who were available for further evaluation, one is alive with persistent disease and eight patients have experienced further relapses. Two patients, both treated in continuous remission were in complete remission at last follow-up, 36+ and 48+ months after HDC. One of them had been treated for a local relapse (femur) and one for bilateral pulmonary metastatic relapse. In both cases, complete surgery followed by conventional chemotherapy with two cycles of carboplatinum/etoposide had preceded HDC. The conditioning regimens for autologous stem cell transplantation were melphalan/etoposide in the first case and melphalan/etoposide/carboplatinum in the second.
Discussion
High-dose chemotherapy followed by autologous stem cell transplantation has been widely used for many solid tumors of childhood. In spite of many trials, there is still no proven role for this treatment with the exception of neuroblastomas and probably relapsed or metastatic Ewing's sarcomas.
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935 Table 2 Treatment and outcome of patients with relapsed osteosarcoma Med. = mediastinum; Lo = local; Pu = pulmonary; AWD = alive with disease; DOC = death of complication; R = relapse; NR = no response; NE = not evaluable; C = carboplatinum; E = etoposide; IFO = ifosphamide; CYC = cyclophosphamide; DOD = died of disease.
Table 3
Conditioning regimens used for HDC in relapsed osteosarcoma patients At present, there are only a few reports available dealing with high-dose chemotherapy in osteosarcoma patients. Several protocols have been developed using alkylating agents since an apparent dose-response relationship has been demonstrated with this group of drugs. 14, 15 On the other hand, high-dose carboplatinum and etoposide have been shown to be effective in relapsed sarcomas. The conditioning regimens for peripheral stem cell transplantation in our study varied. The largest subgroup (seven patients) received high-dose chemotherapy based on melphalan and etoposide with or without carboplatinum. Within this subgroup, one patient died of toxic complications and two patients are in continuous remission after 36 and 48
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Bone Marrow Transplantation months, respectively. Both of these patients were in complete remission when HDC was performed. Among our patients who received double high-dose therapy, two died of treatment-related complications and the remainder experienced further relapses or showed resistant disease. Chan et al 6 reported experiences using high-dose thiotepa and melphalan in a panel of solid tumors including two osteosarcomas. Despite good response rates in neuroblastomas and Ewing's sarcomas, both osteosarcomas were resistant. In another trial, seven patients with osteosarcoma were treated with high-dose thiotepa followed by HSCT. 14 All patients had detectable tumor at the time of HDC. After HDC, four patients showed partial tumor regression. Different conditioning regimens either using exclusively alkylating agents (busulfan, melphalan and thiotepa) or busulfan and melphalan in combination with etoposide were used for HDC of high-risk solid tumors in children by Perentesis et al. 4 This study showed a better outcome in patients who were transplanted while they were in complete remission (CR). In our study both patients who are still in CR were also treated with HDC after a CR was achieved.
Our retrospective analysis shows that HDC in this group of patients did not significantly improve the outcome for patients with relapsed or metastatic osteosarcoma over that reported for conventional treatment. 16 However, while this paper describes one of the largest cohorts of osteosarcoma patients treated by HDC and ASCT ever reported, the number of patients was nevertheless limited and HDC was heterogeneous. Therefore, further studies would be necessary before any value of HDC for patients with relapsed osteosarcomas could be assumed. Based on the two disease-free survivors in our analysis, HDC including carboplatinum and etoposide in combination with alkylating agents such as thiotepa or melphalan might be considered for such trials. This suggestion is supported by promising results after high-dose chemotherapy based on carboplatinum and etoposide in relapsed osteosarcomas. 17 However, HDC is clearly not sufficient to circumvent the well-known deleterious consequences which accompany any failure to achieve a complete surgical remission.
